Episurf Medical AB (publ) ("Episurf") has today entered into a letter of intent with the Canadian company Oligo Medic Inc. ("Oligo Medic") regarding a possible divestment of Episurf's medical technology business. The letter of intent forms part of the strategic review of the medical technology business announced by Episurf on 26 october 2026 and of the Company's refocusing on property operations.
Oligo Medic is developing an international platform for joint-preserving treatments under the planned name FOREVER IN MOTION. The platform is intended to combine complementary technologies within, among other areas, biomaterials, individualized implants, surgical treatment and digital motion analysis. Episurf's Episealer® implant and Epiguide® instruments are expected to add further technological breadth and clinical experience to the platform.
"We view positively the opportunity to find a long-term industrial solution for our medical technology business. Episurf has developed a unique technology with extensive clinical experience. Through Oligo Medic's broader platform, the business can be given better conditions for continued product development and international commercialization. For Episurf, a divestment would at the same time be an important step in our refocusing and in our efforts to concentrate our resources on the property business."
- Jens Andersson, CEO Episurf Medical
The parties will now continue work on the transaction structure and a possible final transfer agreement. No divestment has been completed. A transaction is subject to the parties reaching a final agreement, the fulfilment of applicable conditions and the adoption of the requisite resolutions. Episurf will publish further information when there is reason to do so.
For further information, please contact:
Jens Andersson, CEO, Episurf Medical
Tel: +46 (0) 768 55 67 02
Email: jens.andersson@episurf.se
About Episurf Medical AB
Episurf Medical is a property company with exposure to a diversified portfolio of property assets. The Company's objective is to create value growth through the acquisition and management of Nordic properties. The Company also has a medical technology operation based on the individualized implant Episealer® and associated surgical instruments, which are used to treat cartilage injuries in joints. Episurf Medical's head office is in Stockholm, Sweden.
This press release has been published in Swedish and English. In the event of any discrepancy between the language versions, the Swedish version shall prevail.